Emerging preclinical evidence highlights beneficial microbiota transplantation and metabolic intervention (e.g., short-chain fatty acids and tryptophan derivatives) as potent adjuvants to PD-1/PD-L1 blockade, achieving near-abrogation of tumor growth in murine models (10, 11). This evidence concerns the gene CD274 and neoplasm.